Literature DB >> 33922851

Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis.

Anca Elena Gogu1, Andrei Gheorghe Motoc2, Alina Zorina Stroe3, Any Docu Axelerad3, Daniel Docu Axelerad4, Ligia Petrica5,6, Dragos Catalin Jianu1,7.   

Abstract

Cerebral venous sinus thrombosis (CVST), accounting for less than 1% of stroke cases, is characterized by various causes, heterogeneous clinical presentation and different outcome. The plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms has been found to be associated with CVST. The aim of this retrospective study was to determine the potential association of PAI-1 675 4G/5G polymorphisms and homocysteine levels with cardiovascular risk factors in a group of young patients with CVST. Eighty patients with CVST and an equal number of age and sex matched controls were enrolled. The protocol included demographic and clinical baseline characteristics, neuroimagistic aspects, genetic testing (PAI-1 675 4G/5G polymorphisms), biochemical evaluation (homocysteine-tHcy, the lipid profile, blood glucose, glycohemoglobin-HbA1c, high-sensitive C-reactive protein-hsCRP) data, therapy and prognosis. The PAI-1 675 4G/5G gene polymorphisms were significantly correlated with increased homocysteine level (tHcy) (p < 0.05), higher total cholesterol (TC) (p < 0.05), low- density lipoprotein cholesterol (LDLc) (p = 0.05) and high- sensitive C- reactive protein (hsCRP) (p < 0.05) in patients with CVST when compared with controls. From the PAI-1 gene polymorphisms, the PAI-1 675 4G/5G genotype presented statistically significant values regarding the comparisons of the blood lipids values between the CVST group and control group. The homocysteine (tHcy) was increased in both groups, patients versus controls, in cases with the homozygous variant 4G/4G but the level was much higher in the group with CVST (50.56 µmol/L vs. 20.22 µmol/L; p = 0.03). The most common clinical presentation was headache (91.25%), followed by seizures (43.75%) and focal motor deficits (37.5%). The superior sagittal sinus (SSS) was the most commonly involved dural sinus (56.25%), followed by the lateral sinus (LS) (28.75%). Intima-media thickness (IMT) values were higher in the patients' group with CVST (0.95 mm vs. 0.88 mm; p < 0.05). The fatal outcome occurred 2.5% of the time. PAI-1 675 4G/5G gene polymorphisms and higher homocysteine concentrations were found to be significantly associated with CVST in young patients.

Entities:  

Keywords:  PAI-1 gene polymorphisms; cerebral venous sinus thrombosis; homocysteine

Year:  2021        PMID: 33922851     DOI: 10.3390/metabo11050266

Source DB:  PubMed          Journal:  Metabolites        ISSN: 2218-1989


  30 in total

1.  Increased lipoprotein(a) levels are not a steady prothrombotic defect.

Authors:  W Korte; J Greiner; A Feldges; W F Riesen
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

2.  Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease.

Authors:  Elizabeth A Varga; Amy C Sturm; Caron P Misita; Stephan Moll
Journal:  Circulation       Date:  2005-05-17       Impact factor: 29.690

Review 3.  Diabetes mellitus as a prothrombotic condition.

Authors:  P J Grant
Journal:  J Intern Med       Date:  2007-08       Impact factor: 8.989

4.  PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting.

Authors:  R Marcucci; D Brogi; F Sofi; C Giglioli; S Valente; A Alessandrello Liotta; M Lenti; A M Gori; D Prisco; R Abbate; G F Gensini
Journal:  Heart       Date:  2005-07-01       Impact factor: 5.994

5.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

Review 6.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

7.  The national glycohemoglobin standardization program: a five-year progress report.

Authors:  R R Little; C L Rohlfing; H M Wiedmeyer; G L Myers; D B Sacks; D E Goldstein
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

8.  Diagnosis and management of a young woman with acute isolated lateral sinus thrombosis.

Authors:  Dragoş Cătălin Jianu; Silviana Nina Jianu; Andrei Gheorghe Marius Motoc; Mărioara Poenaru; Ligia Petrica; Adrian Vlad; Sorin Ursoniu; Anca Elena Gogu; Traian Flavius Dan
Journal:  Rom J Morphol Embryol       Date:  2017       Impact factor: 1.033

9.  Cerebral microangiopathy in patients with non-insulin-dependent diabetes mellitus.

Authors:  Ligia Petrica; Maxim Petrica; Mircea Munteanu; Adrian Vlad; Flaviu Bob; Cristina Gluhovschi; Gheorghe Gluhovschi; Catalin Jianu; Adalbert Schiller; Silvia Velciov; Virginia Trandafirescu; Gheorghe Bozdog
Journal:  Ann Acad Med Singapore       Date:  2007-04       Impact factor: 2.473

10.  Homocystine levels, polymorphisms and the risk of ischemic stroke in young Asian Indians.

Authors:  Arijit Biswas; Ravi Ranjan; Arvind Meena; Mohammad Suhail Akhter; Birendra Kumar Yadav; Murali Munisamy; Vivekanandhan Subbiah; Madhuri Behari; Renu Saxena
Journal:  J Stroke Cerebrovasc Dis       Date:  2009 Mar-Apr       Impact factor: 2.136

View more
  2 in total

Review 1.  An Integrated Approach on the Diagnosis of Cerebral Veins and Dural Sinuses Thrombosis (a Narrative Review).

Authors:  Dragos Catalin Jianu; Silviana Nina Jianu; Traian Flavius Dan; Georgiana Munteanu; Alexandra Copil; Claudiu Dumitru Birdac; Andrei Gheorghe Marius Motoc; Any Docu Axelerad; Ligia Petrica; Sergiu Florin Arnautu; Raphael Sadik; Nicoleta Iacob; Anca Elena Gogu
Journal:  Life (Basel)       Date:  2022-05-11

2.  Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Presenting as Recurrent Ischemic Stroke: The Microthrombi Shower.

Authors:  John Dayco; Taha Ataya; Chad Tidwell; Abdalaziz M Awadelkarim; Rashid Alhusain; Mohammed Ali; Adnan Halboni; John Dawdy; Randy Lieberman
Journal:  Cureus       Date:  2022-04-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.